Leuko: Funding, Investors & Team (Sep 2026)
Leuko Labs has created a non-invasive device for monitoring white blood cells. Assessing white blood cells is crucial in many medical situations, such as managing chemotherapy and detecting serious infections. Currently, this test is invasive and not easily accessible, requiring patients to travel for blood draws and lab tests. With Leuko Labs' PointCheck device, immunosuppressed patients can now undergo more frequent testing, leading to better quality of life and clinical outcomes.
Leuko has raised $9.5M across 2 funding rounds on record, the most recent an undisclosed round of $4.5M announced in Jul 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Leuko Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Leuko Funding Rounds
Leuko raised $5.0M in a Series A announced in Sep 2022.
1.8 years later, an undisclosed round of $4.5M was announced in Jul 2024.
Leuko Founders and Leadership Team
Contact details for the Leuko team: 2 of 2 have an email address on file.
Start 14-day free trial →Leuko Funding Compared to Other Biotechnology Startups
Leuko's latest round of $4.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Leuko in Biotechnology and Boston
Companies Similar to Leuko
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Leuko Funding FAQs
What does Leuko do?
Leuko Labs has created a non-invasive device for monitoring white blood cells. Assessing white blood cells is crucial in many medical situations, such as managing chemotherapy and detecting serious infections. Currently, this test is invasive and not easily accessible, requiring patients to travel for blood draws and lab tests. With Leuko Labs' PointCheck device, immunosuppressed patients can now undergo more frequent testing, leading to better quality of life and clinical outcomes.
How much funding has Leuko raised?
Leuko has raised $9.5M across 2 rounds on record. The most recent is an undisclosed round of $4.5M announced in Jul 2024.
When did Leuko last raise funding?
Leuko's most recent funding round on record is an undisclosed round of $4.5M, announced in Jul 2024.
Who founded Leuko?
FundedIQ lists Ian Butterworth (Founder) at Leuko.
Who is the CEO of Leuko?
Carlos Castro Gonzalez is listed as CEO at Leuko.
Where is Leuko headquartered?
Leuko is based in Boston, Massachusetts, United States.
How many employees does Leuko have?
Leuko is in the 11-50 employee band.
How does Leuko's funding compare to other Biotechnology startups?
Leuko's latest round of $4.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Leuko Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Leuko is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.